Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Indacaterol acetate/glycopyrronium bromide/mometasone furoate (Enerzair® Breezhaler®) is recommended as an option for use within NHS Wales for the maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long‑acting beta2‑agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year. |
|||
|
|||
Medicine details |
|||
| Medicine name | indacaterol / glycopyrronium / mometasone (Enerzair Breezhaler®) | ||
| Formulation | 114 micrograms/ 46 micrograms/ 136 micrograms inhalation powder, hard capsules | ||
| Reference number | 3141 | ||
| Indication | Maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long‑acting beta2‑agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year |
||
| Company | Novartis Pharmaceuticals UK Ltd | ||
| BNF chapter | Respiratory system | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 0721 | ||
| NMG meeting date | 14/04/2021 | ||
| AWMSG meeting date | 19/05/2021 | ||
| Date of issue | 24/05/2021 | ||